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Abstract
Gliomas are the most common type of primary brain tumor in adults. High-grade neoplasms are associated with
poor prognoses, whereas low-grade neoplasms are associated with 5-year overall survival rates of approximately
85%. Despite considerable progress in treatment modalities, the outcomes remain dismal. As is the case with many
other tumors, gliomas express or secrete several immunosuppressive molecules that regulate immune cell function.
Programmed death-ligand 1 (PD-L1) is a coinhibitory ligand that is predominantly expressed by tumor cells.
The binding of PD-L1 to its receptor PD-1 has been demonstrated to induce an immune escape mechanism
and to play a critical role in tumor initiation and development. Encouraging results following the blockade of
the PD-1/PD-L1 pathway have validated PD-L1 or PD-1 as a target for cancer immunotherapy. Studies have
reported that the PD-1/PD-L1 pathway plays a key role in glioma progression and in the efficacy of immunotherapies.
Thus, progress in research into PD-L1 will enable us to develop a more effective and individualized immunotherapeutic
strategy for gliomas. In this paper, we review PD-L1 expression, PD-L1-mediated immunosuppressive mechanisms, and
the clinical applications of PD-1/PD-L1 inhibitors in gliomas. Potential treatment strategies and the challenges that may
occur during the clinical development of these agents for gliomas are also reviewed.
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Background
Gliomas account for 51.4% of all primary brain tumors and
are thus the most common primary brain tumor in adults
[1]. The World Health Organization (WHO) classifies gli-
omas as low-grade gliomas (LGGs) and high-grade gliomas
(HGGs) according to aggressiveness. The 5-year overall
survival (OS) rate of LGG patients is approximately 85%.
However, the survival rate of HGG patients is less than 5%
with the standard treatment of total surgical resection
followed by radiotherapy and adjuvant chemotherapy [2].
The ability of gliomas to induce local and systemic im-
munosuppression limits the innate defense against tumor
growth and the efficacy of adaptive immunotherapy and
thus poses a significant challenge to the development of
new therapies [3]. T lymphocytes have the potential to
recognize antigens [4]. Immune checkpoints, particularly
programmed cell death (PD)-1 receptor and its ligand
(PD-L1), can suppress the activity of T lymphocytes
[5]. The consequences of the binding of PD-1 to PD-L1
are apoptosis and the exhaustion of activated immune
cells. Wei et al. [6] outlined the multitude of effects that
are exerted on PD-1/PD-L1 by T cells, which induce the
loss of proliferation and diminished cytokine production.
In the past 5 years, immunotherapy with PD-1 and PD-L1
monoclonal antibodies (mAbs) has resulted in significant
benefits, with durable responses and acceptable
treatment-related toxicities in several types of tumors.
Pembrolizumab and nivolumab (NIVO) (two checkpoint
inhibitors that target PD-1) were approved by the Food
and Drug Administration (FDA) for advanced melanoma
therapy in late 2014 and for non-small cell lung cancer
(NSCLC) therapy in March 2015 [7–10].
The success of immunotherapy in other cancers and
the current understanding of the interaction between
tumors and the immune system have generated increa-
sing interest in the use of PD-1/PD-L1 inhibitors in the
treatment of gliomas, particularly glioblastomas (GBMs).
The first large phase III trial of NIVO in patients with
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GBM (CheckMate 143, NCT02017717) was initiated in
January 2014 and is ongoing. Given that the PD-1/PD-L1
pathway is critical for downregulating the immune
responses of gliomas, we reviewed its expression, the me-
diated immunosuppressive mechanisms, and the clinical
applications of PD-1/PD-L1 inhibitors. We also consi-
dered potential treatment strategies and the challenges
that may occur during the clinical development of these
agents in gliomas.
PD-L1 expression and prognosis value in gliomas
The expression of PD-L1 has been detected in glioma cell
lines and tumor tissue. The expression of PD-L1 was de-
tected in glioma cell lines as early as 2003 by Wintterle et
al. [11]. They found that all 12 tested malignant glioma
cell lines expressed PD-L1 mRNA. A subsequent study
from Wilmotte et al. [12] revealed that the PD-L1 protein
was also observed in 6/8 human astrocytoma cell lines.
Immunohistochemical (IHC) studies have characterized
PD-L1 expression in the cytoplasm and/or the cell
membranes of glioma samples. The positive rate of PD-L1
protein expression was variable across different studies
and ranged from 6.1 to 100%. Pooled analysis demon-
strated an overall positive rate of PD-L1 protein expres-
sion of 44.72% (Table 1). A study with a small sample of
10 patients demonstrated that PD-L1 protein expression
was detected in all 9 glioblastoma (WHO IV) specimens
and in 1 mixed glioma (WHO III) specimen [11]. How-
ever, in a large series of human glioma samples involving
345 patients, the rate of PD-L1 expression positivity was
found to be only 6.1%; specifically, positivity was found in
0/54 grade I/II, 0/47 grade III, and 21/244 grade IV
gliomas (3 gliosarcoma and 18 GBM cases) [13]. However,
there were substantial variations in the sample sizes, the
ratios of the different pathological grades, the methods of
preparing the tumor tissues, the antibodies used, and the
diagnosis standards, including the expression patterns and
positivity cut-offs, among these studies, which contributed
to the biases in the results; these differences are characte-
rized in Table 1. Therefore, further research to establish
uniform standards is necessary.
Recent studies have investigated the distribution of PD-L1
expression in glioma tissues. The patterns of PD-L1
expression were described as two main staining patterns:
diffuse/fibrillary patterns and membranous patterns. Further
analyses revealed no significant difference in the extent of
diffuse/fibrillary or membranous PD-L1 expression between
newly diagnosed and matched recurrent glioblastoma speci-
mens [14]. Yao et al. [15] investigated the heterogeneity of
PD-L1 expression in the subsites of glioma tumor tissues.
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(Spring Biosciences)
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Pooled data 957 44.7
Abbreviations: IHC immunohistochemistry, IFC immunofluorescence histochemistry, WB western blot, PE paraffin-embedded specimens, NM not mentioned
aCut-off value to determine positivity
bThe rates of patients with glioblastomas with any PD-L1 protein expression on tumor cells
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The results revealed that PD-L1 expression was significantly
greater at the edges of the tumors than in the tumor cores
(P= 0.001), and this finding may be related to the invasion
of gliomas. Upregulation of PD-L1 at the edge of the tumor
forms a barrier between the tumor cells and cytolytic T cells;
this phenomenon has been termed a “molecular shield” and
contributes to the high rate of malignant infiltration and the
escape from immune surveillance during invasion into the
adjacent brain tissue.
To date, all of the relevant studies have demonstrated
that the expression of PD-L1 in tumor tissues is correlated
with glioma grade, which demonstrates that PD-L1 may
be a candidate tissue biomarker for gliomas. Wilmotte et
al. [12] found that PD-L1 staining in HGGs not only was
more intense but revealed a greater proportion of positive
cells (>30% stained cells) than in diffuse astrocytomas and
oligodendrogliomas (18/33 vs. 1/12, P < 0.001, χ2 test). In
another study, in which 48 patients with gliomas were en-
rolled, western blot analyses revealed a significantly higher
level of PD-L1 expression in HGGs (n = 24) than in LGGs
(n = 24; P < 0.001) [15]. Baral et al. [16] reported that the
expression of PD-L1 in freshly dissected human glioma
tissues is correlated with the glioma grade. These findings
suggest that the growth of the most malignant forms of
glioma is promoted by the selection of tumor cells with a
high level of PD-L1, which facilitates immune evasion.
The selection of tumor cells with high levels of PD-L1 fa-
cilitates immune evasion and thus favors the growth of
the most malignant forms of glioma. Thus, PD-L1 may be
a potential biomarker and new therapeutic target for
gliomas.
Major research efforts have been made to evaluate the
prognostic value of PD-L1 in gliomas. In a study of 229
glioma (grades I–IV) patients, Zeng et al. [17] found no
significant associations between PD-L1 expression and
OS. Using the median survival time (12 months) as a
cut-off point, these authors found that a high level of
PD-L1 expression was significantly associated with the
poor OS of patients who survived and were followed up
over 12 months. Several studies have been conducted to
determine the prognostic value of PD-L1 in the GBM
subtype. However, the results have been inconsistent.
Liu et al. [18] were the first to report that PD-L1 expres-
sion is a negative prognosticator for survival based on a
very small series of 17 GBM cases. In a retrospective
study by Berghoff et al. [14], who investigated PD-L1
expression in 563 GBMs and its correlation with patient
outcome, the presence of diffuse/fibrillary PD-L1 expres-
sion was not associated with survival time in a cohort of
117 specimens of newly diagnosed GBM. Based on level
2 Agilent microarray gene expression, there was also no
significant association between the PD-L1 gene expres-
sion level and OS in 446 patients with GBM from The
Cancer Genome Atlas (TCGA) dataset. However, using
level 3 Illumina RNASeq, Nduom et al. [19] found a
significant association between PD-L1 gene expression
and outcome in the same TCGA dataset. The median
survival of the high-expression PD-L1 mRNA group was
significantly shorter than that of the low-expression
group (11.42 vs. 14.9 months, respectively; P = 0.023).
The patients with high PD-L1 expression levels (dichoto-
mized into low and high at the cut-off point 0.37) exhib-
ited a significantly increased risk of death compared
with patients with low expression levels (P = 0.0231),
and PD-L1 was an independent factor that was
negatively associated with survival (P = 0.0343). The
prognostic influence of PD-L1 expression at the protein
level was evaluated in a survival analysis of 94 GBM
samples. Using the median as the cut-off point, the
patients with >2.77% PD-L1-positive cells exhibited a
trend toward worse OS (P = 0.066). However, when a
cut-off of 5% positive cells was used, as has been used in
numerous other studies of solid malignancies, high
expression was associated with a significantly shorter
survival (P = 0.0086), which confirmed the results
obtained with the mRNA data. The different PD-L1
expression threshold levels and assay technologies (e.g.,
the Agilent microarray and the Illumina RNASeq) likely
contributed to these inconsistent conclusions [20].
Therefore, further studies are required to determine the
prognostic value of PD-L1 in gliomas.
PD-L1-mediated immunosuppressive and
upregulation mechanisms in glioma
Gliomas have long been recognized as immunosuppres-
sive neoplasms that are characterized by the activation of
various immune escape mechanisms. The coinhibitory
characteristics of the PD-L1 molecule are attributed to the
binding of this molecule to its receptor, PD-1, on tumor-
specific T cells. This binding leads to apoptosis of the
tumor-specific T cells and subsequently provides an
immune escape for glioma cells that is similar to that of
several types of extracranial tumors, including melanoma,
lung cancer, gastric cancer, Ewing sarcoma, and head and
neck cancer [21, 22]. The process of immunosuppression
is correlated not only with the abnormal expression of
PD-L1 on glioma cells but also with the microenviron-
ment that tumor cells depend on. It has been reported
that PD-L1 is expressed at a higher level in tumor-
infiltrating macrophages in gliomas, which possibly leads
to passive immunosuppressive effects due to T:T cell inter-
actions [23]. Additionally, normal monocytes that are
exposed to malignant glioma cells can significantly
increase PD-L1 expression and assume a myeloid-derived
suppressor cell (MDSC)-like phenotype. These MDSCs
are characterized by the expression of PD-L1 and possess
immunosuppressive activities, which result in the induc-
tion of apoptosis in activated T cells, and these cells have
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the ability to stimulate regulatory T cell proliferation [24].
More recently, PD-L1 expression in neuronal cells in the
glioma microenvironment and post-transcriptional regula-
tion by the endogenous production of interferon (IFN)-β
have been reported. More importantly, PD-L1 expressed
on neurons induces the caspase-dependent apoptosis of
glioma cells, which results in longer survival times and
suggests that the microenvironment can play a positive
role in the inhibition of glioma growth [18].
The upregulation of PD-L1 on tumor cells plays a sig-
nificant role in the immune escape mediated by gliomas.
The mechanisms of the upregulation of PD-L1 in gliomas
are illustrated in Fig. 1. The upregulation of PD-L1-
mediated evasion of tumor immunity has been termed
“adaptive resistance,” stemming from the observations
that extrinsic induction of PD-L1 is largely mediated by
IFN-γ. IFN-γ is a proinflammatory cytokine mainly gene-
rated by T lymphocytes after antigen recognition and acti-
vation in adaptive immunity. Upon recognition of tumor
antigens, T effector cells or tumor-infiltrating lymphocytes
(TILs) produce IFN-γ, which drives PD-L1 expression in
the tumor cells. Adaptive resistance is supported by flow
cytometry-based observations that IFN-γ can induce high
levels of cell surface PD-L1 expression in all 12 glioma cell
lines [11]. In addition to the upregulation of PD-L1 in the
protein level, IFN-γ could also increase the expression of
PD-L1 mRNA [25]. IFN-γ induced PD-L1 transcription in
lung carcinoma cells via binding on two interferon regula-
tory factor 1 sites (200 and 320 base pairs upstream of the
transcriptional start site) in the promoter of PD-L1 [26].
Recent studies suggested that the activation of nuclear
factor-kappaB is essential for IFN-γ-induced PD-L1 up-
regulation in human melanoma cells [27], and the
PKD2 signal pathway is also involved in this upre-
gulation on human oral squamous carcinoma [28].
Hypoxia is a well-recognized tumor microenviron-
mental condition. Hypoxia-inducible factor-1 plays a
critical role in the regulation of cellular responses to
hypoxia. It regulates the expression of PD-L1 by bin-
ding directly to the hypoxia response element-4 in
the PD-L1 proximal promoter [29] (Fig. 1, left).
Constitutive oncogenic signals are shown to mediate
intrinsic induction of PD-L1 as an “innate resistance”
mechanism of immune evasion. This is evidenced by the
small fraction of human cancers that lack TILs in the
tumor microenvironment but still express high levels of
PD-L1 [30, 31]. Parsa et al. [32, 33] measured the
expression of PD-L1 in glioma cells and found that
glioma cells with genetic deletions or mutations of the
phosphatase and tensin homolog (PTEN) genes exhibit
Fig. 1 Adaptive resistance and innate resistance. (Left, adaptive resistance) Upon recognition of tumor antigens, TILs produce IFN-γ, which
induces PD-L1 expression via nuclear NF-κB activation and the PKD2 signal pathway. In tumor hypoxia microenvironmental condition,
HIF-1 regulates the expression of PD-L1 by binding directly to the hypoxia response element-4 in the PD-L1 proximal promoter. Upon
binding to PD-1, PD-L1 delivers a suppressive signal to T cells, leading to T cell dysfunction. (Right, innate resistance) Tumor cell PD-L1
expression that might be related to oncogenic signaling pathways or oncogenic gene mutation as inherent in the tumor cell. Oncogenic
signals (such as PI3K/Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathway) or oncogenic gene mutation (such as PTEN, ALK, and EGFR)
upregulate PD-L1 expression on tumors as innate resistance. Abbreviations: IFN-γ interferon-γ, TILs tumor-infiltrating lymphocytes, NF-κB
nuclear factor-kappaB, PI3K phosphatidylinositol 3-kinase, HIF-1 hypoxia inducible factor-1, JAK/STAT3 Janus kinase/signal transducer and
activator of transcription 3, EGFR/MAPK epidermal growth factor receptor/mitogen-activated protein kinase, ALK anaplastic lymphoma kin-
ase, PKD2 polycystin 2, PD-1 programmed death 1, PD-L1 programmed cell death-ligand 1, AKT protein kinase B, mTOR mammalian target
of rapamycin, PTEN phosphatase and tensin homolog
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greater PD-L1 protein levels than cells with wild-type
PTEN. Further research demonstrated that the PI(3)K-
Akt-mTOR-S6K1 pathway increases the PD-L1 protein
level, which results in gliomas that are inherently resistant
to immunoreaction. So far, no general oncogenic signaling
or oncogenic gene mutation is shown to mediate intrinsic
induction of PD-L1. Depending on cell type, the expres-
sion of PD-L1 was found to correlate with various onco-
genic signaling or oncogenic gene mutations, such as the
Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathways
[34–36] or PTEN, ALK, and EGFR mutations [37–39]
(Fig. 1, right). MicroRNA (miRNA) is a small non-coding
RNA molecule that functions in RNA silencing and post-
transcriptional regulation of gene expression [40]. miR-
34a and miR-200 have an inverse relationship with PD-L1
expression, which points to the role of epigenetic regula-
tion in the regulation of PD-L1 in cancer cells [41, 42].
Recent findings have supported the notion that PD-L1
upregulation in tumor cells is related to both innate and
adaptive resistance mechanisms. Han et al. [43] found that
the expression levels of the PD-L1 transcript and protein
are increased in both PTEN− and PTEN+ cell lines when
the glioma cell lines are treated with IFN-γ. Additionally,
IFN-γ induces significantly greater increases in the levels of
PD-L1 protein and transcript in PTEN− tumor cells than
in PTEN+ tumors. Coculture experiments have revealed
that the activated oncogenic PI3K pathway participates in
immune evasion through PD-L1 superinduction, which is
mediated by IFN-γ in PTEN-deficient gliomas. In summary,
these data indicate that complicated mechanisms of PD-L1
upregulation exist in gliomas owing to the unique tumor
microenvironment and complex signaling pathways.
Glioma treatment using a PD-1/PD-L1 blocking
antibody
Combination therapy strategy and preclinical research
The blockade of PD-1/PD-L1 can elicit effective anti-tumor
T cell responses. In the past 5 years, the targeting of the PD-
1/PD-L1 axis has been at the forefront of immunotherapy
due to its remarkable clinical efficacy in melanoma and
non-small cell lung cancer clinical trials [44, 45]. There is a
growing interest in the development of combinatorial im-
munotherapy strategies for cancer treatment. An increasing
number of preclinical studies in mouse models of GBM in-
volving the orthotopic implantation of GL261 cells have
demonstrated that combination treatment with PD-1 and a
PD-L1 inhibitor can successfully treat the tumors.
Most of the preclinical research into gliomas involved tar-
geting the PD-1/PD-L1 axis in addition to other immuno-
suppressive inhibitors. Huang et al. [46] reported the
median survival of the mice that received the PD-1-
inhibited natural killer (NK) cell treatment was prolonged to
44 longer days compared with 35 days in the NK cell treat-
ment group and 29 days in the control group in an
orthotopic glioma stem cell-like mouse model. The study in-
dicated that the blockade of the PD-1/PD-L1 axis may pro-
mote the cotoxicity of NK cells against GSCs. Indoleamine
2,3-dioxygenase (IDO) is a tryptophan catabolic enzyme that
is overexpressed in both antigen-presenting cells and tumor
cells and enables tumor cells to escape from the immune re-
sponse. The expression of IDO has been described in 96%
of GBMs and is correlated with overall patient survival [47].
Wainwright et al. [48] administered 1-MT (an IDO inhibi-
tor) alone or in combination with a cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4) mAb, a PD-L1 mAb, or both
CTLA-4 and PD-L1 mAbs to mice with orthotopically im-
planted GL261 cells. The results demonstrated that only the
group that was treated with the combination of all three, i.e.,
the PD-L1 mAb, the CTLA-4 mAb, and 1-MT, exhibited
significantly better survival. Additionally, this group exhib-
ited a significant immune response as demonstrated by the
lowest level of immunosuppressive regulatory T cells and
the highest levels of CD4+IFN-γ and CD8+IFN-γ.
Combination treatment with a PD-1/PD-L1 inhibitor
and radiotherapy (RT) is an attractive option given the
potential for increased tumor antigen release and presen-
tation. RT counteracts the immunosuppressive tumor
microenvironment by enhancing the presentation of nor-
mally suppressed tumor-associated antigens, increasing
the expression of major histocompatibility complex class I
and proinflammatory cytokines, promoting dendritic cell
maturation and downregulating Fas ligand expression. RT
can foster dendritic cell maturation and promote CD8+ T
cell recruitment into tumors [49]. In preclinical trials,
anti-PD-1/PD-L1 combined with RT improved local con-
trol and survival, and this finding provided an important
developmental direction for combined treatment. Zeng et
al. [50] tested the combination of anti-PD-1 immunother-
apy and stereotactic radiosurgery (SRS) in an orthotopi-
cally implanted GL261 cell mouse model. With the RT
plus anti-PD-1 treatment, the median survival was pro-
longed to 52 days (P < 0.001) compared with 27 days in
the RT-alone group and 30 days in the anti-PD-1
monotherapy group, and 15 to 40% of the mice became
long-term survivors (>90 days after implantation). On day
21 after implantation, infiltration by cytotoxic T cells had
increased and regulatory T cell levels had decreased in the
combined treatment group compared with the single-
modality arms. T cell immunoglobulin mucin-3 (TIM-3)
is another immune checkpoint molecule and acts as a
negative regulator of the immune system [51]. Kim et al.
[52] evaluated a combination of anti-TIM-3 antibody and
anti-PD-1 immunotherapy and SRS in an orthotopic
mouse GBM model. The triple-modality treatment (anti-
PD-1 + SRS + anti-TIM-3) yielded a robust increase in the
OS of 100% by day 146 (P < 0.05) compared with the other
treatment arms. This triple-modality treatment increased
the infiltrations of IFN-γ+ and tumor necrosis factor-α+
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CD4 T cells as well as IFN-γ+ CD8 lymphocytes into the
tumor. These findings indicate that anti-PD-1/PD-L1
pathway treatment combined with SRS may be a feasible
treatment strategy in gliomas.
Bevacizumab is a humanized mAb that targets vascu-
lar endothelial growth factor and became the third drug
approved by the FDA for use in recurrent GBM in 2009
[53]. However, the addition of bevacizumab to standard
therapy in newly diagnosed glioblastoma patients has
demonstrated no improvement in OS [54]. The clinical
responses of anti-VEGF treatment are transient; clinical
relapse usually occurs within months after an initial re-
sponse. By contrast, cancer immunotherapies can elicit
durable and striking clinical activities [55]. Thus, it is
reasonable to assume that the combination of bevacizu-
mab with immunotherapy is a favorable approach. In-
deed, combined therapy using PD-1/PD-L1 axis
blockade and anti-VEGF treatment has demonstrated
encouraging antitumor activity and tolerable adverse
events in some animal models and in clinical studies [56,
57]. There are also some crucial considerations to ac-
count for in the development of targeted therapy and
immunotherapy combinations, which include the
optimization of dosing regimens and the minimization
of treatment-related toxicities.
Clinical studies of PD-1/PD-L1 targeting in glioma
Clinical trials
Clinical trials have been initiated to determine the
potential of PD-1/PD-L1 checkpoint inhibitors as
monotherapies and combination therapies for glioblas-
tomas (Table 2).
NIVO is a fully human IgG4 subtype antibody that tar-
gets human PD-1 with a stabilizing hinge region mutation
that is resistant to the exchange of IgG4 molecules. The
FDA has approved NIVO for unresectable or metastatic
melanomas and NSCLCs. NIVO is currently being investi-
gated as a monotherapy for GBM in a phase II trial
(NCT02550249). Ongoing trials of NIVO in combination
with galunisertib (a kinase inhibitor of TGFβRI) are being
conducted in patients with GBM (NCT02423343). Ipili-
mumab (IPI) is a fully humanized mAb against CTLA-4
and was approved by the FDA in 2011 for advanced
melanoma [58–60]. Based on the safety and efficacy
observed in melanoma [61], the combination of IPI and
NIVO was tested in recurrent GBM. This was a phase III
randomized trial (CheckMate 143, NCT02017717) that
enrolled patients with GBM on December 17, 2013, and
the study began on January 6, 2014. The updated results
presented in 2016 at the American Society of Clinical
Oncology (ASCO) Annual Meeting demonstrated encou-
raging efficacy outcomes in the completed phase I cohorts
1 and 1b. Among 40 patients with a first recurrence of
GBM following radiation and temozolomide, 20 patients
(cohort 1) were randomized 1:1 to NIVO 3 mg/kg (N3)
every 2 weeks (Q2W) or NIVO 1 mg/kg + IPI 3 mg/kg
every 3 weeks (Q3W; N1 + I3) for four doses followed by
N3 Q2W. Twenty patients in cohort 1b received NIVO
3 mg/kg + IPI 1 mg/kg Q3W (N3 + I1) for four doses
followed by N3 Q2W. Stable disease or better was










PD-1 NCT02550249 Nivolumab II Primary and
recurrent GBM
Preoperative neoadjuvant June 2015 Recruiting
participants
NCT02423343 Nivolumab I/II Recurrent or refractory
NSCLC HCC GBM




Nivolumab III Recurrent GBM Alone or in combination
with the IPI Compared to
bevacizumab
January 2014 Ongoing




NCT02337491 Pembrolizumab II Recurrent GBM With or without bevacizumab February 2015 Ongoing




NCT01952769 Pidilizumab I/II DIPG and recurrent
GBM
Alone February 2014 Recruiting
participants






NCT01375842 MPDL3280A I Solid tumors
(include GBM)
Alone June 2011 Recruiting
participants
This information of clinical trials came from the web site of clinicaltrials.gov (The last search was conducted on October 15, 2016).
Abbreviations: GBM glioblastoma, NSCLC non-small cell lung cancer, HCC hepatocellular carcinoma, NIVO nivolumab, IPI ipilimumab, DIPG diffuse intrinsic
pontine glioma
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achieved in 6/10, 4/10, and 9/20 patients who were treated
with N3, N1 + I3, and N3 + I1, respectively. The OSs at
12 months were 40% (95% CI 12–67), 30% (95% CI 7–58),
and 25% (95% CI 8–48) in the N3, N1 + I3, and N3 + I1
groups, respectively [62]. Furthermore, NIVO in combin-
ation with IPI and chemotherapy will be tested in patients
with GBM. There is an ongoing phase I safety study that
was planned to investigate IPI and NIVO in combination
with temozolomide for recurrent GBM (NCT02311920).
Pembrolizumab is a humanized monoclonal IgG4 anti-
PD-1 antibody consisting of a high-affinity mouse anti-
PD-1-derived variable region grafted onto a human IgG4
immunoglobulin molecule with an engineered Fc region
for stabilization. Pembrolizumab was approved in 2014
by the FDA for the treatment of patients with IPI-
treated advanced melanoma [63]. In a recent phase II
clinical trial, patients with untreated brain metastases
from melanomas or NSCLCs were treated with 10 mg/
kg pembrolizumab every 2 weeks until progression.
Responses of the CNS lesions were achieved in four
(22%; 95% CI 7–48) of 18 patients with melanoma and
in six (33%; 95% CI 14–59) of 18 patients with NSCLC
[64]. Pembrolizumab is currently being tested in
combination with bevacizumab (NCT02337491) and
with MRI-guided laser ablation (NCT02311582) in pa-
tients with recurrent GBM. Additionally, the anti-PD-1
antibody pidilizumab is a humanized mAb that modu-
lates the immune response, and evaluation in patients
with metastatic melanoma revealed an OS at 12 months
of 64.5% [65]. A randomized phase I/II study has been
planned to test the effect of pidilizumab against diffuse
intrinsic pontine glioma and recurrent GBM
(NCT01952769).
In addition to the PD-1 inhibitors discussed above, there
are two anti-PD-L1 agents that are currently being evalu-
ated in clinical trials for gliomas. The human anti-PD-L1
antibody MEDI4736 has demonstrated a durable response
in patients with melanoma and NSCLC [66], and
MEDI4736 is now being tested in combination with radio-
therapy and bevacizumab in the treatment of GBM
(NCT02336165). MPDL3280A, which is also a human
anti-PD-L1 monoclonal antibody, has received a
breakthrough therapy designation from the FDA for PD-
L1-positive urothelial bladder cancer and NSCLC. A
current phase I study is investigating the safety and
pharmacokinetics of MPDL3280A as administered as a
single agent to patients with solid tumors, including GBM
(NCT01375842). The relative paucity of clinical trials of
anti-PD-L1 inhibitors may be because PD-L1 is located in-
side tumor cells. PD-L1 inhibitors would have to penetrate
both the blood-brain barrier and the blood-tumor barrier
to be effective [67]. Moreover, because the expressions of
PD-L2 and possibly other tumor-associated molecules
may play roles in tolerating PD-1-expressing lymphocytes,
the magnitude of the anti-tumor immune response could
also be blunted [68].
Adverse events
The aim of antibodies that target either PD-1 or PD-L1 is
to block the PD-1/PD-L1 pathway with the goal of adjust-
ing and normalizing immunity to a desirable level while not
enhancing immunity in general [69]. The achievement of
this aim may provide an explanation as to why PD-1 and
PD-L1 inhibitors have resulted in dramatic clinical efficacies
with reduced toxicities. To date, data regarding the adverse
events associated with these glioma treatments are still lim-
ited. There is only one report of a clinical trial (CheckMate
143), which was presented at the 2015 and 2016 ASCO An-
nual Meetings [62, 70]. The preliminary results regarding
drug-related adverse events from a phase I safety cohort 1
trial were reported at the 2015 ASCO Annual Meeting
[70]. The events associated with N3 were all grade 1 or 2
and included fatigue (n = 3) and nausea (n = 3). For the N1
+ I3 group, the adverse events included fatigue (n = 8), diar-
rhea (n = 7), increases in glutamic oxalacetic aminopherase
and lipase (n = 5 each), increases in vomiting and alanine
aminotransferase (n = 4 each), and amylase increase,
headache, hyperthyroidism, nausea, and maculo-papular
rash (n = 3 each). Among these N1 + I3 patients, 8/10
developed grade 3–4 adverse events. Treatment discontinu-
ation due to drug-related adverse events, which included
colitis, cholecystitis, diabetic ketoacidosis, confusion, and
increased lipase, occurred in only 5 patients with N1 + I3.
Updated results regarding adverse events were presented at
the 2016 ASCO Annual Meeting [62]. In the N3, N1 + I3,
and N3 + I1 groups, any-grade treatment-related adverse
events were reported in 9/10, 10/10, and 20/20 patients,
respectively, and the corresponding proportions for grade
3–4 adverse events were 0/10, 9/10, and 5/20. In the N3,
N1 + I3, and N3 + I1 groups, any-grade treatment-related
serious adverse events were observed in 2/10, 7/10, and 5/
25 patients, respectively, and the corresponding propor-
tions for grade 3–4 adverse events were 0/10, 7/10, and 2/
20. Treatment discontinuation due to treatment-related ad-
verse events was required in none of the N3 patients, 3 of
the N1 + I3 patients, and 1 of the N3 + I1 patients. Encour-
agingly, no treatment-related deaths have occurred in this
cohort. Adverse events associated with PD-1 inhibition in
patients with brain metastases in a phase II trial have been
reported in detail, and these results could provide import-
ant information [64]. These results demonstrated that pem-
brolizumab was well tolerated in 36 patients with brain
metastases (18 with melanoma and 18 with NSCLC). In the
melanoma cohort, only a single patient developed severe
adverse events (grade 3), and the grade 1–2 adverse events
were fatigue (n = 8), anorexia (n = 1), dermatological issues
(n = 6), arthralgias (n = 2), and endocrine problems (n = 1).
In the NSCLC cohort, the serious adverse events included
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(one patient each) acute kidney injury (grade 2), pneumo-
nitis (grade 3), colitis (grade 3), hyperkalemia (grade 4), and
fatigue (grade 3). The grade 1–2 adverse events included
colitis or diarrhea (n = 3), acute kidney injury (n = 1), fatigue
(n = 5), anorexia (n = 3), dermatological problems (n = 4),
arthralgias (n = 1), endocrine problems (n = 5), and
hematologic effects (n = 2). Neurological adverse events
were also reported in the clinical trial, and to the best
of our knowledge, data regarding PD-1 and PD-L1 in-
hibitors remain scarce [64]. The neurological adverse
events were grades 1–2, and none led to treatment discon-
tinuation. Eight of 18 patients in the melanoma cohort
developed neurological adverse events that included grade
3 cognitive dysfunction (n = 1), grade 1–2 seizures (n = 3),
headache (n = 3), and dizziness (n = 1); in addition, 2 of
these patients developed neurologic symptoms due to
peri-lesional edema (1 developed grade 3 cognitive
dysfunction, and 1 developed grade 2 seizures). The
neurological adverse events in the NSCLC cohort were
grades 1–2 and included cognitive dysfunction (n = 1),
headache (n = 4), dizziness (n = 2), and stroke (n = 1).
There were no treatment-related deaths or autoimmune
events, which indicated the safety of the blocking PD-1 or
PD-L1 antibodies in patients with CNS tumors.
Current challenges
There are some challenges to the clinical application of
targeting the PD-1/PD-L1 axis as a therapeutic modality
in patients with glioma. First and the most important,
biomarkers that identify patients who are likely to respond
to PD-1 or PD-L1 inhibition have not been defined. Al-
though PD-L1 immunohistochemistry has been approved
by the FDA as the only predictive companion diagnostic
test for the use of pembrolizumab in NSCLC patients, im-
proved survival outcomes have been observed in many
PD-L1-negative patients [71]. Additionally, standardized
methods for the detection of PD-L1 and a scoring cut-off
for determining PD-L1 positivity in glioma cells are
lacking. Second, the criteria for the assessment of the
responses of solid tumors to conventional therapy are the
Response Evaluation Criteria, which may not be well
suited to immunotherapy. Immunotherapy Response As-
sessment in Neuro-Oncology criteria are currently being
drafted by a multinational panel to standardize the
response assessment criteria for patients with neuroonco-
logical malignancies and to prevent premature termin-
ation of immunotherapies, including anti-PD-1/PD-L1
therapies, due to pseudoprogression [72]. Third, both
preclinical and clinical studies of anti-PD-1/PD-L1 in
gliomas are still limited. Last, research efforts have focused
on anti-PD-1/PD-L1 therapies combined with other
treatment modalities, including chemotherapy, molecular
targeted agents, and RT, in gliomas. The optimal sequence
of the combination and the suitable dose and fractionation
of RT should be confirmed. Future research should aim to
develop new effective agents or optimal combined treat-
ment strategies that elicit the lowest toxicities to improve
the outcomes of glioma.
Conclusions
PD-L1 is expressed in glioma cells, correlates with tumor
grade, and contributes to immunoresistance. The PD-1/
PD-L1 pathway plays an important role in glioma biology.
The use of anti-PD-1/PD-L1 antibodies in immunothera-
peutic strategies for gliomas is attracting increasing atten-
tion. With the goal of improving the efficacy of anti-PD-1/
PD-L1 immunotherapy, many studies have focused on
combination treatment, including the targeting of multiple
immune inhibitors, RT, ablation, chemotherapy, and other
molecular targeting therapies. Because there is a need for
better and safer treatment strategies for gliomas, the
initiation of a greater number of successive clinical trials
associated with immune checkpoint blockade along with
further exploration into the mechanism of tumor immu-
nity would be warranted.
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